Abstract
Introduction
The central theme of biotechnology is using biological systems, an organism or any part of it, for derivation of special products or services to satisfy human need. A major part of the knowledge and discipline involves developing the organism or an appropriate part of it for the purpose, generating the product and processing.
The origin of the technology is often traced to making yogurt by using bacteria or fermenting beer by yeast.
Before 1970s, the methods for getting a better organism were limited to searching among natural variants, selective breeding, hybridization, and induced mutation by chemical and physical agents. Despite some significant successes, this traditional biotechnology was not a well-known scientific discipline.
However, the nature of biotechnology was changed forever when Stanley Cohen and Herbert Boyer invented the recombinant DNA technology (also called molecular biotechnology, genetic engineering, gene cloning, gene splicing or gene transplantation) in 1973. DNA or Deoxyribonucleic Acid is at the root of all inherited characteristics of an organism. DNA contains the genes -functional units of heredity each bearing a message of hereditary characteristic. The above scientists invented methods of recombining genes from different sources, thus producing "Genetically Engineered" ( G E) or "Genetically Modified" (GM) organisms with newer characteristics. 1 1. Identifying a gene (unit of inheritance) with desirable characteristic in one organism.
2. Isolate the gene 3. Introduce the gene to and express the characteristic in another organism [1] [2] [3] [4] Before the advent of the above technology genetic materials of two organisms could be combined almost exclusively through sexual reproduction, which was possible only within a species and between closely related species or genera. Cross or hybridization, that is, sexual union crossing the species boundary, often resulted in sterile offspring. By hybridization technique it was impossible to combine genes, say of, rice and carrot, tomato and cow, etc. The molecular biotechnology or genetic engineering opened up the possibility of transferring characteristics of one organism to another, irrespective of their relationship, that is, a bacterial characteristic to a plant or even a human characteristic to a bacterium could be transferred by transferring one's gene to the other.
Along with the development of recombinant DNA technology other molecular biological techniques as sequencing, DNA s y nthesis, gene expression regulation, monoclonal antibody production, cell culture and stem cell differentiation, aided by bioinformatics -hybrid off shoot of biotechnology with modern computing device, h a ve brought revolutions in medicine: developed quick methods for diagnosing infection or monitoring cholesterol levels, generated series of new drugs, vaccines, and completely novel classes of therapeutic agents, forced breakthroughs in understanding diseases as diverse as cystic fibrosis and cancer. Yet the progress so far is considered by many scientists as only a beginning. Within the next two decades, scientists foresee individualized targeted therapies, development of predictive technologies leading to a new era in disease prevention, diagnosis, and treatment. [4] [5] [6] [7] [8] [9] [10] An overview of the subdivisions and scope of biochemistry is illustrated in Figure 1 .
What follows next is a very brief review of the fields of modern biotechnology in prevention, diagnosis and treatment of human diseases; followed by the global picture with particular emphasis to the Asian countries; and prospects, problems of its development and possible strategies of solution in Bangladesh. 
Biotechnology in prevention, diagnosis and treatment

Production of recombinant proteins
Therapeutic proteins
Before the 1980s proteins were rarely used as drugs.
Exceptions were insulin and various vaccines. With the advent of genetic modification, however, human proteins have become available in huge quantities.
The first "bioengineered" drug, a recombinant form of human insulin, was approved by the U.S. Food and Drug Administration (FDA) in 1982. 11 Until then, insulin was obtained from a limited supply of beef or pork pancreas tissue. By inserting the human gene for insulin into bacteria, scientists were able to achieve bacterial production of large quantities of the lifesaving protein. In the near future, patients with diabetes may be able to inhale insulin, eliminating the need for injections. Recombinant DNA products include, human serum albumin, human insulin, interferons, growth hormone, erythropoietin, etc. [12] [13] [14] [15] [16] Human proteins produced by recombinant DNA have several advantages. They are indistinguishable from their authentic human counterparts but are safer as they are less likely to be contaminated by infectious agents, and they can be produced in large quantities. A case in point is human growth hormone, which previously could only be obtained from human cadavers and carried the risk of CreutzfeldJakob disease (CJD). 17 
Biotech vaccines
Biotechnology also plays an important role in preventing disease. Vaccines produced by recombinant DNA m e thods are generally safer than traditional vaccines because they contain isolated viral or bacterial proteins, as opposed to killed or weakened disease-causing agents. However, many citizens in developing nations do not have access to any vaccines, let alone ones derived from biotechnology.
In conventional vaccine production, the pathogen of interest is grown in the laboratory, collected and either killed or severely weakened before being injected into humans. The immune system then produces antibodies against the vaccine, protecting the body against future infection. If a fragment of the microbial DNA is used as an alternative vaccine, this will produce the antigenic protein directly in the body and may induce the immune system to produce antibodies. DNA v a ccines may be safer than conventional ones. They may also be easier t o manufacture and may be stable at room temperature. These traits would greatly facilitate development and distribution of vaccines in the developing world. [18] [19] [20] [21] [22] [23] [24] [25] The first recombinant vaccine, approved in 1986, was produced by slipping a gene fragment from the hepatitis B virus into yeast. 
Transgenic animals
By the early 1980s, scientists were able to insert DNA from humans into mice and other animals. Because they now express human genes, "transgenic" animals can be studied as models for the development of diabetes, atherosclerosis, and Alzheimer's disease. They also can generate large quantities of potentially therapeutic human proteins. For example, a recombinant "clot-buster," expressed in the milk of transgenic goats, currently is being tested in patients. [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] Gene therapy Unlike conventional treatments, which attempt to deal with the consequences of a defect, gene therapy aims to correct the defect itself. In order to function, the therapeutic gene must reach the nucleus of the target cell. Various vectors have been used to achieve this, of which viruses were the first to be investigated. These have a natural ability to enter a cell and become active.
Current gene therapy systems suffer from the inherent difficulties of effective pharmaceutical processing and development, and the chance of reversion of an engineered mutant to the wild type. Potential immunogenicity of viral vectors involved in gene delivery is also problematic. [56] [57] To address this issue, nanotechnological tools in human gene therapy have been tested and nanoparticle-based nonviral vectors (usully in size) in transportation of plasmid DNA d e scribed. Therefore, successful introduction of less immunogenic nanosize gene carriers as a substitution of the disputed viral vectors seems beneficial in repairing or replacing impaired genes in human. [58] [59] [60] Whatever the vector, there are two methods by which gene therapy can be carried out: 1. in vivo gene therapy, in which the vector is injected into the body and has to find its way to the target tissue 2. ex vivo in which a sample of tissue is taken from the patient, treated with the vector and then replaced. 61 Currently active trials of gene therapy are going on over such varied diseases cystic fibrosis, vein graft rejection, psychiatric d i sorders, inner ear developmental anomalies, brain tumors, mitochondrial genetic diseases. [61] [62] [63] [64] [65] [66] [67] [68] [69] The use of viruses to deliver genes has shown risks to human health, making trials with these viruses controversial. Another method involves the use of liposomes, hollow membranous spheres which encapsulate the gene. Liposomes fuse with the cell membrane, releasing their gene into the cytoplasm. 66, 69 The convergence of nanotechnology with biotechnology will allow for safer gene delivery methods that are not based on viruses. Chemically synthesized nanoparticles that carry genes or therapeutics specifically to diseased cells are currently being tested in animals. 69 
Antisense technology
In 1978, Paul Zamecnik of Harvard University demonstrated that the DNA to protein mechanism could be interrupted by the use of small synthetic stretches of DNA called oligonucleotides. He used an oligonucleotide with a sequence complementary to an mRNA molecule needed by a particular virus to reproduce itself. The oligonucleotide bound to the mRNA and stopped it moving onto the ribosome for translation. Early work is in progress to develop antisense technology as specific DNA drugs against cancer, viral infection and Crohn's disease (an inflammatory condition of the bowel). Polymerase chain reaction (PCR) Biotechnology also has dramatically improved diagnostic capabilities. The polymerase chain reaction, a method for amplifying tiny bits of DNA first described in the mid-1980s, a single segment of gene could be identified, copied, and tested within hours. It has been crucial to the development of blood tests that can quickly determine exposure to the human immunodeficiency virus (HIV), for example. Genetic testing currently is available for many rare disorders, such as hemophilia, which is caused by a mutation in a single gene. Little can be done to prevent or slow some of these diseases, however, and the underpinnings of more complex illnesses such as cancer, heart disease, and mental illness are as yet not well understood. Soon after their invention in 1970's the monoclonal antibodies (mAbs) earned the reputation of 'magic bullet,' in particular against tumor specific antigens and infectious diseases. 108 The molecular biological techniques augmented both its accuracy and versatility. 109 Present antibody based therapeutics include unconjugated mAbs, antibody drug conjugates (ADC1), antibody based radioconjugates (ARC), bispecific antibodies (BsAb) recognizing two different antigens, Ab fragments and Fc fusion proteins. [110] [111] [112] Antibodies and antibody fragments can be relatively easily modified by molecular biological techniques. [113] [114] [115] [116] Bioinformatics With the help of bioinformatics-powerful computer programs capable of analyzing billions of bits of genomic sequence data-scientists are cracking the genetic codes to use the information for achieving various medical goals. For example by analyzing the codes of bacteria and discovering "weak spots" vulnerable to attack by compounds identified via high-throughput screening. This kind of work led in 2000 to the approval of Zyvox, the first entirely new antibiotic to reach the market in 35 years. [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] Genomics and sequencing of human genome The sequencing of the human genome, completed just three years ago, also has given scientists an incredibly rich "parts list" with which to better understand why and how disease happens. In the foreseeable future not only will every human gene will be identified, but the factors controlling their expression will also be known. This knowledge will unlock new targets for diagnosis, treatment and prevention of disease. It will change medicine forever, allowing treatments to become increasingly tailored to the specific needs of the individual. [129] [130] [131] [132] [133] [134] [135] [136] [137] Proteomics Proteomics is about analyzing the complete set of expressed proteins in a given cell, 138 the path was open to understand emergent properties that result from the complex interactions of metabolic and regulatory networks.
The technical cornerstone of proteomics is the high throughput mass-spectrometry-based identification and quantification of proteins. 139 Proteomics is being used to unravel protein constellation of the cell, virulence factors, deranged host proteins, hostpathogen interactions, identification of microorganisms, characteristics of genes and genomes, and also for designing drugs against diseases including cancer, cardiovascular and infectious diseases. Using technologies such as mass spectrometry can detect protein biomarkers in the blood that may indicate early signs of disease, even before symptoms appear. One such marker is C-reactive protein, an indicator of inflammatory changes in blood vessel walls that presage atherosclerosis. [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] Microarray technology Nano-biotechnology Nano-biotechnology or nanomedicine is another rapidly moving field. Nanosensors are being developed from particles that are about 50,000 times smaller than the diameter of human hair to detect protein and gene expression in individual cells in the body, thus allowing the assessment of the health of cells at early stages of disease. Scientists are developing a wide variety of nanoparticles and nanodevices, scarcely a millionth of an inch in diameter, to improve detection of cancer, boost immune responses, repair damaged tissue, and thwart atherosclerosis.
Nano-biotechnology can develop powerful diagnostic tools for the isolation and diagnosis of various diseases. [196] [197] Drugs can be delivered as nanoparticles to targeted sites, including locations that cannot be easily reached by standard drugs. [198] [199] [200] [201] Many agents, which cannot be administered orally due to their poor bioavailability, can be delivered with the help of nanotechnology. [202] [203] [204] Nano-formulations protect drugs from degradation or denaturation and prolong half-life. [183] [184] N a notechnology can be applied to deliver antigens for vaccination. [205] [206] [207] [208] [209] Global picture of biotechnology with emphasis to the Asian countries In all Asian countries, the governments are the ones driving biotech research. Private industry's role, in comparison, is miniscule. This is mainly because biotech research requires large investments in infrastructure and has a high cash-burn rate, while the returns in the initial years are quite low. Strong research-focused private players are rapidly emerging in countries such as China [211] [212] , India [213] [214] [215] [216] , Taiwan [217] [218] [219] , South Korea [221] [222] , and Singapore. [222] [223] [224] China forayed into biotech with a focus on plant genomics and transgenic technology. It was the only country from Asia that participated in the human genome project and is now shoring up its genome sequencing capability to facilitate the sequencing of microbial genomes. India was amongst the front runners in biotechnology initiatives in agriculture and now there is an increasing interest in the field of medical biotechnology from the private sector with quite a few players. [211] [212] The government of India has established the Department of Biotechnology under the Ministry of Science and Technology, with huge budget to boost the advancement of biotechnology. The Government of India also took collaborative programs with UNESCO to establish the Regional Centre for research, training and education in biotechnology under the auspices of UNESCO. India is already being globally recognized as a manufacturer of economical, high-quality bulk drugs and formulations. With a huge base of talented, skilled and costcompetitive manpower, and a well-developed scientific infrastructure, it has great potential to become a leading global player in biotechnology. [214] [215] In India the biotech industry has been growing at a double-digit rate over the last five years. The industry size stood at $4 billion for financial year 2010-11. Indian biopharmaceutical industry constitutes 60% of the biotech industry and grew at 21% to reach $2.3 billion in 2010-11. Vaccines, insulin, erythropoietin and monoclonal antibodies have been the mainstay of the biopharmaceuticals segment. 216 Taiwan's medical bio-technology industry began in 1984 with government funding qualified laboratories to run recombinant DNA technology experiments. Today, it has plans for a number of investment projects including science-based industrial parks, research incentives and a combination of public and private funding. [217] [218] [219] South Korea, for example, has identified four key sectors for development and growth, namely, genetic engineering, proteomics, bioinformatics and disease treatments. [221] [222] Singapore, too, has identified four key areas for structural improvement and better links between researchers and industry. It has perhaps a more coherent strategy than most others, with a very strong national planning. [222] [223] [224] Applications in medical biotechnology are the more lucrative option for Asian countries, but this has high entry barriers and investment needs. With Asia's emergence as a preferred manufacturing base for bulk drugs and pharmaceutical dosage forms, and clinical development; it would be a move up the value chain for these players to extend these capabilities in chemistry into biology. The potential is furthered by the biopharmaceutical industry's rich research pipeline and greater expected therapeutic efficacy of clinical candidates for current lifestyle diseases.
About $126 billion worth of branded drugs are to go off-patent in the next 5 years, (from June 2012). While innovation is essential for sustainable longterm success, generic markets and services sector offers robust growth prospects. Asian firms can be expected to gain a strong foothold in the world generics markets given their strong chemistry and reverse engineering skills.
Challenges for Bangladesh
Biotechnology in general and Medical Biotechnology in particular is definitely a very prospective area of development for developing countries like Bangladesh, as the example of India shows. In Bangladesh although some biotechno-logical work and industrial initiatives in the traditional sense of the term has been taken, the field of modern medical biotechnology is still untouched. Only a few successful attempts has only been taken by international institutions in Bangladesh as ICDDRB. The national institutions are yet to prove their capabilities and potentials.
A summary analysis of the situation in Bangladesh is given in the form of SWOT analysis below.
SWOT analysis of Bangladesh
Strengths
Rich biodiversity Low cost of labor in research, development and manufacturing Fairly trained human resource
Weakness
Lack of commitment and patriotism, and too much corruption and irresponsibility on part of the political and bureaucratic establishment are the major weaknesses regarding development of the country in general, and biotechnology in particular.
Emigration of the experts to rich countries Unawareness on part of entrepreneur community Disinterest in investing in research and development (R & D) by the national entrepreneurs Weak connection to the knowledge and information network 
Concluding remarks
Biotechnology has the potential to provide more and healthier foods, reduce dependence on fossil fuels, offers more effective cures, diagnosis and prevention of diseases. It could be a shining path for industrial and economic development through generation of products and services both for domestic consumption and export.
The weaknesses on part of Bangladesh as noted above are addressable. However, the government must be the supporter and major investor in this effort, as the initial phase of development involves good amount of investment which would give only a delayed and diffused return, which the private sector is incapable to undertake.
The most optimistic feature of this fledgling technology and the industry is that: 
